US-based provider of mobile technology for heart health AliveCor has launched its third-generation device, the Heart Monitor.
The Heart Monitor is designed to record, store and transfer single-channel electrocardiography (ECG) rhythms.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It also displays ECG rhythms and detects the presence of atrial fibrillation (AF) when prescribed or used under the care of a physician.
The monitor can be used by healthcare professionals, patients with known or suspected heart conditions and health conscious individuals.
The US Food and Drug Administration (FDA) cleared ECG monitor was designed in collaboration with global design firm IDEO, based on first-hand customer feedback.
AF affects more than 140 million people worldwide and the company is focused on helping those with diagnosed and undiagnosed heart conditions, by providing patients and caregivers a tool to detect and manage heart conditions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUsers of AliveCor’s Heart Monitor are recording 130,000 ECGs per month and actively tracks more than 10,000 symptoms, medications and activities that may affect an individual’s wellbeing.
University of California San Francisco heart and vascular centre cardiology division co-director Jeffrey Olgin said: "The AliveCor Heart Monitor leads to results that I can use to manage my patients remotely, a trend that is here to stay.
"Seeing my patients’ ECG results in real-time is the next best thing to having them in my office when the event takes place."
The new heart monitor is compatible with the free AliveECG app and will be available through AliveCor’s collaboration with Omron Healthcare, a manufacturer of home blood pressure monitors.
AliveCor president Euan Thomson said: "Big data and personalised medicine are revolutionising the delivery of care and have the potential to disrupt the way we think about healthcare.
"The newest generation of the Heart Monitor confirms AliveCor’s ongoing commitment to help stop the unnecessary loss of life and healthcare costs driven by undiagnosed and under-managed heart arrhythmias that lead to potentially life-threatening conditions like strokes."
The company said the new mobile ECG device is available for $74.99 and is not intended for paediatric use. In January 2015, the monitor will also be available on Amazon.
Image: Third generation AliveCor Heart Monitor. Photo: courtesy of PRNewswire / AliveCor Inc.
